Patents by Inventor Robert M. Hoffman

Robert M. Hoffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11963681
    Abstract: A surgical instrument comprises a body, shaft, and end effector. The shaft couples the end effector and body together. The end effector comprises an anvil and lower jaw configured to receive a surgical staple cartridge. The anvil is configured to pivot toward and away from the staple cartridge and lower jaw. The shaft assembly comprises a knife member configured to longitudinally translate to thereby substantially simultaneously cut clamped tissue and staple the severed tissue. The end effector may comprise lockout features configure to prevent longitudinal translation of the knife member. The end effector or staple cartridge may comprise lockout bypass features configured to prevent lockout of the knife member. These lockout bypass features may operate to permit longitudinal translation of the knife member once or multiple times. The end effector may comprise features configured to ensure proper alignment of the anvil relative to the staple cartridge.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: April 23, 2024
    Assignee: Cilag GmbH International
    Inventors: Jason M. Rector, Douglas B. Hoffman, Robert J. Simms, John C. Schuckmann, Ryan J. Laurent, Frederick E. Shelton, IV, Jeffrey C. Gagel, Nicholas Fanelli
  • Patent number: 11938326
    Abstract: Implantable medical systems enter an exposure mode of operation, either manually via a down linked programming instruction or by automatic detection by the implantable system of exposure to a magnetic disturbance. A controller then determines the appropriate exposure mode by considering various pieces of information including the device type including whether the device has defibrillation capability, pre-exposure mode of therapy including which chambers have been paced, and pre-exposure cardiac activity that is either intrinsic or paced rates. Additional considerations may include determining whether a sensed rate during the exposure mode is physiologic or artificially produced by the magnetic disturbance. When the sensed rate is physiologic, then the controller uses the sensed rate to trigger pacing and otherwise uses asynchronous pacing at a fixed rate.
    Type: Grant
    Filed: February 18, 2022
    Date of Patent: March 26, 2024
    Assignee: Medtronic, Inc.
    Inventors: Hyun J. Yoon, Wade M. Demmer, Matthew J. Hoffman, Robert A. Betzold, Jonathan D. Edmonson, Michael L. Ellingson, Mark K. Erickson, Ben W. Herberg, Juliana E. Pronovici, James D. Reinke, Todd J. Sheldon, Paul R. Solheim
  • Patent number: 11871731
    Abstract: A transplantation method to increase the establishment rate of human tumors in immunodeficient mice. A pocket is created in the mouse and the tumor and surrounding tissues are implanted in the pocket. The pocket is left open to oxygenate the tumor and surrounding tissues.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: January 16, 2024
    Assignee: ANTICANCER, INC.
    Inventors: Robert M. Hoffman, Chihiro Hozumi
  • Patent number: 11873519
    Abstract: A composition and method for reversing or preventing age-related metabolic and tissue degenerative changes in individuals. The method includes administering, orally, an effective amount of a first composition having methioninase enzyme. The method further includes administering, by a route other than the oral route, such as a parenteral route, an effective amount of a second composition having methioninase enzyme. The method further includes the steps of orally and/or parentally administering pyridoxal-L-phosphate.
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: January 16, 2024
    Inventors: Qinghong Han, Robert M Hoffman
  • Publication number: 20220340891
    Abstract: A composition and method for lowing serum and plasma levels of methionine by oral administration. The composition includes a recombinant methioninase enzyme and a cofactor (pyridoxal-L-phosphate). Methods of use describe methods for treatment of cancer, including malignant melanoma, by oral administration of the methioninase composition. Methods for chronic suppressive therapy of melanoma and other cancers are described. Because reduction of plasma methionine levels is effective in treating other conditions, including diabetes and conditions associated with aging, the use of the methods described herein includes treatment of these and other conditions.
    Type: Application
    Filed: May 25, 2022
    Publication date: October 27, 2022
    Inventors: Qinghong Han, Robert M Hoffman
  • Patent number: 11371036
    Abstract: A composition and method for lowing serum and plasma levels of methionine by oral administration. The composition includes a recombinant methioninase enzyme and a cofactor (pyridoxal-L-phosphate). Methods of use describe methods for treatment of cancer, including malignant melanoma, by oral administration of the methioninase composition. Methods for chronic suppressive therapy of melanoma and other cancers are described. Because reduction of plasma methionine levels is effective in treating other conditions, including diabetes and conditions associated with aging, the use of the methods described herein includes treatment of these and other conditions.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: June 28, 2022
    Inventors: Qinghong Han, Robert M Hoffman
  • Publication number: 20210254040
    Abstract: A composition and method for lowing serum and plasma levels of methionine by oral administration. The composition includes a recombinant methioninase enzyme and a cofactor (pyridoxal-L-phosphate). Methods of use describe methods for treatment of cancer, including malignant melanoma, by oral administration of the methioninase composition. Methods for chronic suppressive therapy of melanoma and other cancers are described. Because reduction of plasma methionine levels is effective in treating other conditions, including diabetes and conditions associated with aging, the use of the methods described herein includes treatment of these and other conditions.
    Type: Application
    Filed: April 8, 2021
    Publication date: August 19, 2021
    Applicant: AntiCancer Inc.
    Inventors: Qinghong Han, Robert M. Hoffman
  • Patent number: 11001826
    Abstract: A composition and method for lowing serum and plasma levels of methionine by oral administration. The composition includes a recombinant methioninase enzyme and a cofactor (pyridoxal-L-phosphate). Methods of use describe methods for treatment of cancer, including malignant melanoma, by oral administration of the methioninase composition. Methods for chronic suppressive therapy of melanoma and other cancers are described. Because reduction of plasma methionine levels is effective in treating other conditions, including diabetes and conditions associated with aging, the use of the methods described herein includes treatment of these and other conditions.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: May 11, 2021
    Assignee: ANTICANCER, INC.
    Inventors: Qinghong Han, Shukuan Li, Yuying Tan, Kei Kawaguchi, Robert M. Hoffman, Sant Chawla
  • Publication number: 20200029540
    Abstract: A transplantation method to increase the establishment rate of human tumors in immunodeficient mice. A pocket is created in the mouse and the tumor and surrounding tissues are implanted in the pocket. The pocket is left open to oxygenate the tumor and surrounding tissues.
    Type: Application
    Filed: July 26, 2019
    Publication date: January 30, 2020
    Inventors: Robert M. Hoffman, Chihiro Hozumi
  • Publication number: 20190153421
    Abstract: A composition and method for lowing serum and plasma levels of methionine by oral administration. The composition includes a recombinant methioninase enzyme and a cofactor (pyridoxal-L-phosphate). Methods of use describe methods for treatment of cancer, including malignant melanoma, by oral administration of the methioninase composition. Methods for chronic suppressive therapy of melanoma and other cancers are described. Because reduction of plasma methionine levels is effective in treating other conditions, including diabetes and conditions associated with aging, the use of the methods described herein includes treatment of these and other conditions.
    Type: Application
    Filed: October 19, 2018
    Publication date: May 23, 2019
    Inventors: Qinghong Han, Shukuan Li, Yuying Tan, Kei Kawaguchi, Robert M. Hoffman, Sant Chawla
  • Publication number: 20190011434
    Abstract: The present invention describes an in vitro test for drug sensitivity for each cancer patient that is performed with a patient's tumor tissue obtained by surgery or biopsy on an automated tissue processor using multi-well tissue-culture plates containing approximately 1 mm3 tumor tissue culture medium and cancer drug. The present invention will accurately identify both effective and in effective drugs for each patient.
    Type: Application
    Filed: July 6, 2018
    Publication date: January 10, 2019
    Inventor: Robert M. Hoffman
  • Publication number: 20180236011
    Abstract: Methods using chemotherapy drugs promote targeting of S. typhimurium A1-R of melanoma, thereby enhancing efficacy against the melanoma PDOX. A metastatic melanoma obtained from the right chest wall of a patient was previously established orthotopically in the right chest wall of nude mice as a patient-derived orthotopic xenograft (PDOX) model. We previously showed that the combination of tumor targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) and chemotherapy was highly effective against the melanoma PDOX. In the present study, we investigated the mechanism of the high efficacy of this combination. Combination therapy significantly increases S. typhimurium A1-R tumor targeting alone (S. typhimurium A1-R+TEM: p<0.01, S. typhimurium A1-R+VEM: p<0.01).
    Type: Application
    Filed: February 22, 2018
    Publication date: August 23, 2018
    Inventors: Kei Kawaguchi, Robert M. Hoffman
  • Publication number: 20030203351
    Abstract: An in vitro model system for viral infection and for immune response is comprised of a tissue block from adult tonsil or lymph node supported on a matrix which is flexible and porous and wherein the supported tissue block is cultured in a medium whose surface is congruent with the tissue block/matrix interface. The histoculture system can be used to screen for antiviral drugs, to monitor the course of viral diseases, and to monitor an immune response to antigen stimulation.
    Type: Application
    Filed: April 1, 2003
    Publication date: October 30, 2003
    Inventors: Robert M. Hoffman, Leonid B. Margolis
  • Patent number: 6562586
    Abstract: An in vitro model system for viral infection is comprised of a tissue block from adult tonsil or lymph node supported on a matrix which is flexible and porous and wherin the supported tissue block is cultured in a medium whose surface is congruent with the tissue block/matrix interface. The histoculture system can be used to screen for antiviral drugs and to monitor the course of viral diseases.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: May 13, 2003
    Assignee: AntiCancer, Inc.
    Inventors: Robert M. Hoffman, Leonid B. Margolis, Joshua Zimmerberg, Svetlana Glushakova
  • Patent number: 6551772
    Abstract: An in vitro model system for viral infection and for immune response is comprised of a tissue block from adult tonsil or lymph node supported on a matrix which is flexible and porous and wherein the supported tissue block is cultured in a medium whose surface is congruent with the tissue block/matrix interface. The histoculture system can be used to screen for antiviral drugs, to monitor the course of viral diseases, and to monitor an immune response to antigen stimulation.
    Type: Grant
    Filed: February 26, 1999
    Date of Patent: April 22, 2003
    Assignee: AntiCancer, Inc.
    Inventors: Robert M. Hoffman, Leonid B. Margolis
  • Patent number: 4242406
    Abstract: This invention relates to a structural laminate having a plastic surface finish coat laminated to a structural base which has exceptional bond strength between the structural base and the plastic layer with which it interfaces. The structural base comprises a glass reinforced gypsum layer. The plastic laminate portion comprises a plastic surface finish coat, preferably a polyester gel coat or an acrylic resin, bonded to a reinforcing layer of curable polyester or epoxy resin reinforced with glass fibers. The reinforcing layer is adhered to a bonding layer which comprises glass fibers protruding from the reinforcing layer and coated with a limited amount of organic resin such as polyester or epoxy resin. The glass reinforced gypsum layer is applied to the protruding fibers of the bonding layer to form an interface having a bond strength of at least about 150 psi as determined by ASTM C297-68.
    Type: Grant
    Filed: April 30, 1979
    Date of Patent: December 30, 1980
    Assignees: PPG Industries, Inc., United States Gypsum Company
    Inventors: Larbi El Bouhnini, Thomas J. Fitzpatrick, Donald M. Harwick, Robert M. Hoffman, Wayne M. Knoll
  • Patent number: 4030158
    Abstract: A hair brush, particularly useful for blow waving has a back of open frame construction to facilitate the flow of hot air. Folded single bristles are inserted into holes on the front surface of the brush in a staggered relatively uniform arrangement. The bristles are relatively thick in diameter and include a bead at one end to avoid scratching the scalp. The thickness of the bristles enables them to withstand the heat of the air used in blow waving.
    Type: Grant
    Filed: June 3, 1976
    Date of Patent: June 21, 1977
    Assignee: Advance Design Laboratories, Inc.
    Inventors: Michael A. Blair, Robert M. Hoffman